tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Keay Nakae, 299 are a BUY (90.88%), 24 are a HOLD (7.29%), 6 are a SELL (1.82%).
Analyst Keay Nakae, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 42.55% that have a potential upside of 38.4% achieved within 178 days.
Keay Nakae’s has documented 590 price targets and ratings displayed on 49 stocks. The coverage is on Healthcare, Financial Services, Consumer Cyclical sectors.
Most recent stock forecast was given on PRQR, ProQR Therapeutics BV.
Analyst best performing recommendations are on STOK (STOKE THERAPEUTICS).
The best stock recommendation documented was for STOK (STOKE THERAPEUTICS) at 1/5/2026. The price target of $35 was fulfilled within 1 day with a profit of $2.45 (7.53%) receiving and performance score of 75.27.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 15-Sep-2020
$5
$0.15 (3.09%)
$5
10 months 18 days ago
(14-Nov-2025)
9/14 (64.29%)
$0.48 (10.62%)
477
Buy Since 05-Nov-2021
$5
$0.15 (3.09%)
$5
1 years 6 months 1 days ago
(31-Mar-2025)
4/10 (40%)
$1.51 (43.27%)
420
Buy Since 17-Dec-2020
$5
$0.15 (3.09%)
$5
1 years 8 months 11 days ago
(21-Jan-2025)
5/19 (26.32%)
$1.79 (55.76%)
671
Hold Since 29-Dec-2021
$5
$0.15 (3.09%)
$4
4 years 8 months ago
(02-Feb-2022)
2/2 (100%)
$2.11 (73.01%)
1298
Buy Since 05-Mar-2020
$7
$2.15 (44.33%)
$7
5 years 3 months 4 days ago
(28-Jun-2021)
0/6 (0%)
$3.63 (107.72%)
Which stock is Keay Nakae most bullish on?
Which stock is Keay Nakae most reserved on?
What Year was the first public recommendation made by Keay Nakae?
